PMID- 23759738
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 5
IP  - 5
DP  - 2013 May
TI  - Complete remission of platinum-refractory primary Fallopian tube carcinoma with 
      third-line gemcitabine plus cisplatin: A case report and review of the 
      literature.
PG  - 1601-1604
AB  - Primary Fallopian tube carcinoma (PFTC) is a rare but highly aggressive disease. 
      Currently, treatments are similar to those used in epithelial ovarian carcinoma 
      (EOC), however, there are distinct differences between the two diseases. PFTC 
      tends to recur in the retroperitoneal nodes and distant sites more often than 
      EOC. Limited literature with regard to effective agents in platinum-resistant and 
      -refractory (Pt-R) disease exists, particularly after two lines of consecutive 
      treatment. In this case report, a 47-year-old female with PFTC exhibited 
      recurrence in the liver after postoperative chemotherapy. The patient received 
      paclitaxel and cisplatin combination as first-line chemotherapy and topotecan as 
      a second-line treatment, which is considered platinum-refractory. After the 
      second-line treatment failed, this patient received a gemcitabine plus cisplatin 
      combination as third-line chemotherapy for a total of 6 cycles. The liver 
      metastases regressed rapidly and completely. The patient's progression-free 
      survival (PFS) was 10 months and overall survival (OS) was 45 months. In 
      conclusion, gemcitabine and cisplatin combination is an effective regimen for 
      refractory PFTC even after the failure of two previous lines of consecutive 
      chemotherapy and this warrants further independent investigation.
FAU - Xu, Qiuyi
AU  - Xu Q
AD  - Department of Medical Oncology, The First Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang 310003 P.R. China.
FAU - Xu, Nong
AU  - Xu N
FAU - Fang, Weijia
AU  - Fang W
FAU - Zhao, Peng
AU  - Zhao P
FAU - Mao, Chenyu
AU  - Mao C
FAU - Zheng, Yulong
AU  - Zheng Y
FAU - Mou, Haibo
AU  - Mou H
LA  - eng
PT  - Journal Article
DEP - 20130306
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC3678517
OTO - NOTNLM
OT  - complete remission
OT  - gemcitabine
OT  - primary Fallopian tube carcinoma
OT  - refractory
EDAT- 2013/06/14 06:00
MHDA- 2013/06/14 06:01
PMCR- 2013/03/06
CRDT- 2013/06/14 06:00
PHST- 2012/10/25 00:00 [received]
PHST- 2013/01/23 00:00 [accepted]
PHST- 2013/06/14 06:00 [entrez]
PHST- 2013/06/14 06:00 [pubmed]
PHST- 2013/06/14 06:01 [medline]
PHST- 2013/03/06 00:00 [pmc-release]
AID - ol-05-05-1601 [pii]
AID - 10.3892/ol.2013.1232 [doi]
PST - ppublish
SO  - Oncol Lett. 2013 May;5(5):1601-1604. doi: 10.3892/ol.2013.1232. Epub 2013 Mar 6.